| Project Detail |
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) – the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20® is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients’ brain viability, thereby predicting who will benefit from EVT. Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20®, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20® will accelerate stroke management and predict EVT outcome and offer tailored care for each patient. |
